These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7027750)

  • 1. The antidiabetic effect and pharmacokinetic properties of glipizide. Comparison of a single dose with divided dose regime.
    Ostman J; Christenson I; Jansson B; Weiner L
    Acta Med Scand; 1981; 210(3):173-80. PubMed ID: 7027750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus.
    Jaber LA; Ducharme MP; Edwards DJ; Slaughter RL; Grunberger G
    Pharmacotherapy; 1996; 16(5):760-8. PubMed ID: 8888072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Duration of effective hypoglycaemic action of glipizide given once daily (author's transl)].
    Azzopardi J; Campbell IW; Clarke BF; Duncan LJ
    Med Klin; 1975 Jul; 70(28-29):1214-8. PubMed ID: 809650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic equivalence of once- and thrice-daily glipizide.
    Wåhlin-Boll E; Groop L; Karhumaa S; Groop PH; Tötterman KJ; Melander A
    Eur J Clin Pharmacol; 1986; 31(1):95-9. PubMed ID: 3536529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics.
    Groop L; Harno K
    Acta Endocrinol Suppl (Copenh); 1980; 239():44-52. PubMed ID: 6776763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glipizide pharmacokinetics and response in diabetics.
    Huupponen R; Seppälä P; Iisalo E
    Int J Clin Pharmacol Ther Toxicol; 1982 Sep; 20(9):417-22. PubMed ID: 6754633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study.
    Blohmé G; Waldenström J
    Acta Med Scand; 1979; 206(4):263-7. PubMed ID: 116480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired effect of sulfonylurea following increased dosage.
    Wåhlin-Boll E; Sartor G; Melander A; Scherstén B
    Eur J Clin Pharmacol; 1982; 22(1):21-5. PubMed ID: 7047168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of sulfonylureas on the secretion, disposal and effect of insulin.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Eur J Clin Pharmacol; 1982; 22(1):27-32. PubMed ID: 7047169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the benefit of increasing the sulfonylurea dose?
    Stenman S; Melander A; Groop PH; Groop LC
    Ann Intern Med; 1993 Feb; 118(3):169-72. PubMed ID: 8417634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glipizide ('Glibenese') in maturity-onset diabetes mellitus.
    Klaassen CH
    Curr Med Res Opin; 1979; 6(1):8-13. PubMed ID: 378559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
    Ahrén B; Lundquist I; Scherstén B
    Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.
    Wåhlin-Boll E; Almér LO; Melander A
    Clin Pharmacokinet; 1982; 7(4):363-72. PubMed ID: 7116738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients.
    Sartor G; Scherstén B; Melander A
    Acta Med Scand; 1978; 203(3):211-4. PubMed ID: 345754
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses.
    Kradjan WA; Takeuchi KY; Opheim KE; Wood FC
    Pharmacotherapy; 1995; 15(4):465-71. PubMed ID: 7479199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glipizide versus tolbutamide, an open trial. Effects on insulin secretory patterns and glucose concentrations.
    Fineberg SE; Schneider SH
    Diabetologia; 1980 Jan; 18(1):49-54. PubMed ID: 6988265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sulfonylurea on the secretion and disposition of insulin and C-peptide.
    Almér LO; Johansson E; Melander A; Wåhlin-Boll E
    Acta Med Scand Suppl; 1981; 656():11-8. PubMed ID: 7046346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
    Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
    Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperglycaemia and absorption of sulphonylurea drugs.
    Groop LC; Luzi L; DeFronzo RA; Melander A
    Lancet; 1989 Jul; 2(8655):129-30. PubMed ID: 2567896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.